Head-To-Head Survey: iBio (IBIO) versus Its Competitors

iBio (NYSE:IBIO) is one of 452 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare iBio to similar companies based on the strength of its valuation, risk, institutional ownership, dividends, earnings, profitability and analyst recommendations.

Institutional and Insider Ownership

7.9% of iBio shares are held by institutional investors. Comparatively, 39.2% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 0.6% of iBio shares are held by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares iBio and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
iBio	$400,000.00	-$24.91 million	-0.47
iBio Competitors	$440.76 million	-$69.01 million	-9.51

iBio’s competitors have higher revenue, but lower earnings than iBio. iBio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

iBio has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, iBio’s competitors have a beta of 10.47, suggesting that their average share price is 947% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for iBio and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	0	0	1	0	3.00
iBio Competitors	4781	9985	15984	364	2.38

iBio currently has a consensus price target of $5.00, indicating a potential upside of 516.52%. As a group, “Pharmaceutical preparations” companies have a potential upside of 245.24%. Given iBio’s stronger consensus rating and higher possible upside, equities research analysts plainly believe iBio is more favorable than its competitors.

Profitability

This table compares iBio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-73.15%	-45.51%
iBio Competitors	-2,594.67%	-410.78%	-44.82%

Summary

iBio beats its competitors on 7 of the 13 factors compared.

iBio Company Profile

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.